Mark T. Osterman, M.D., MSCE
Mark T. Osterman, M.D., MSCE
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine
Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 N 39th Street
Philadelphia, PA 19104
Division of Gastroenterology
218 Wright-Saunders Building
51 N 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Fax: 215-662-0950
Email:
mark.osterman@uphs.upenn.edu
mark.osterman@uphs.upenn.edu
Publications
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Permanent linkBA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Selected Publications
Osterman MT, Lichtenstein GR: Chapter 116: Ulcerative Colitis. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition. Feldman M, Friedman LS, Brandt LJ (eds.). Saunders Elsevier, Philadelphia, Page: 2023-61, 2016.Scott FI, Osterman MT: Therapeutic drug monitoring of biologic agents. Treatment of Inflammatory Bowel Disease with Biologics. Cheifetz AS, Feuerstein JD (eds.). Springer, 2016 Notes: In press.
Gastonguay MR, Lasch K, Barocas M, Rosario M, Wilbur J, Dirks N, Osterman MT: Vedolizumab efficacy exposure-response relationship for ulcerative colitis patients (GEMINI I) based on causal inference analysis. American Journal of Gastroenterology 2016 Notes: Accepted as poster presentation at the American College of Gastroenterology annual meeting October 2016.
Osterman MT, Sandborn WJ, Colombel J-F, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD: Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. American Journal of Gastroenterology 2016 Notes: In press.
Osterman MT, Roblin X, Glover S, Navaneethan U, Popa MA, Wyant T, James A, Lasch K, Rosario M: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1. Gastroenterology 150: S-105, 2016 Notes: Oral presentation at annual Digestive Disease Week meeting.
Osterman MT, Lichtenstein GR: Medical treatment of perianal Crohn’s fistulae. Pediatric Inflammatory Bowel Disease: Third Edition. Kelsen J, Mamula P, Markowitz J, Baldassano R (eds.). Springer Science+Business Media LLC, New York, 2016 Notes: In press.
Chachu KA, Osterman MT: How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD. Inflammatory Bowel Diseases 2016 Notes: Epub ahead of print.
Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR: Comparative effects of biologics on coronary cardiovascular risk among older patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2016 Notes: Epub ahead of print.
Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD: Association between breast cancer recurrence with immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arhritis and Rheumatology 2016 Notes: In press.
Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Predictors and Clinical Impact of Indeterminate QuantiFERON-TB Gold Testing in Inflammatory Bowel Disease. Pharmacoepidemiology and Drug Safety 2016 Notes: Poster presentation at International Conference on Pharmacoepidemiology and Therapeutic Risk Management.